Patents by Inventor Yongjuan GAO
Yongjuan GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240108743Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.Type: ApplicationFiled: October 24, 2023Publication date: April 4, 2024Inventors: Qiang LI, Yuanli LI, Si CHEN, Zhu WANG, Zhao DONG, Zirui LI, Xinlu MA, Lu YANG, Yongjuan GAO, Yuncheng ZHENG, Naichao SUN
-
Patent number: 11833212Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.Type: GrantFiled: August 2, 2021Date of Patent: December 5, 2023Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.Inventors: Qiang Li, Yuanli Li, Si Chen, Zhu Wang, Zhao Dong, Zirui Li, Xinlu Ma, Lu Yang, Yongjuan Gao, Yuncheng Zheng, Naichao Sun
-
Patent number: 11655292Abstract: The invention provides an antibody and/or an antigen binding fragment that binds to NGF, and the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody and/or its antigen binding fragment provided by the invention has high affinity for NGF and can effectively block the binding between NGF receptor and NGF. This antibody and/or its antigen binding fragment can inhibit the binding activity of NGF and its receptor in vitro, and is suitable for the treatment of pain diseases which are related to the haughty expression or increased expression of NGF.Type: GrantFiled: June 23, 2020Date of Patent: May 23, 2023Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.Inventors: Zhu Wang, Yongjuan Gao, Si Chen, Cecily Rou-Yun Sun, Yuncheng Zheng, Bill Nai-Chau Sun, Qiang Li
-
Patent number: 11471513Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.Type: GrantFiled: November 16, 2016Date of Patent: October 18, 2022Assignees: Ampsource Biopharma Shanghai Inc., Furen Pharmaceutical Group Co., Ltd, Pharmab, Inc., Kaifeng Pharmaceutical (Group) Co., Ltd.Inventors: Qiang Li, Wenchen Zhu, Yuanli Li, Chenggong Zhu, Yongjuan Gao, Zijia Ren, Luyan Zhu, Naichao Sun, Xiaoshan Wang, Bin Liu, Zhi Li, Wenwen Wang, Ming Jiang, Qilei Wang, Lirui Wang, Shuya Wang, Songlin Zhu, Jie Gao, Hongsheng Su
-
Patent number: 11472863Abstract: A hyperglycosylated recombinant human coagulation factor IX (FIX) fusion protein, a preparation method therefor, and use thereof. The fusion protein sequentially comprises, from N- to C-terminus, a human FIX, a flexible peptide linker, at least one human chorionic gonadotropin ? subunit carboxy-terminal peptide rigid unit, and a half-life extending moiety. The fusion protein has a biological activity similar to that of the recombinant FIX, an extended in vivo activity half-life, and reduced immunogenicity, so as to improve pharmacokinetics and pharmacodynamics.Type: GrantFiled: April 10, 2017Date of Patent: October 18, 2022Assignees: Ampsource Biopharma Shanghai Inc., Pharmab, Inc.Inventors: YongJuan Gao, Si Chen, Zirui Li, Xiaoping Tu, Bill Nai-chau Sun, Qiang Li
-
Publication number: 20220105193Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.Type: ApplicationFiled: August 2, 2021Publication date: April 7, 2022Inventors: Qiang LI, Yuanli LI, Si CHEN, Zhu WANG, Zhao DONG, Zirui LI, Xinlu MA, Lu YANG, Yongjuan GAO, Yuncheng ZHENG, Naichao SUN
-
Publication number: 20220033476Abstract: Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-domain, a flexible peptide linker, at least one rigid unit of a carboxyl-terminal peptide of a human chorionic gonadotropin beta subunit, and a half-life prolonging moiety (preferably an IgG Fc variant). The fusion protein has a similar biological activity to a recombinant FVIII, a prolonged active half life in vivo, and better stability in vitro and in vivo, and thus improves the pharmacokinetics and efficacy of the fusion protein.Type: ApplicationFiled: September 24, 2019Publication date: February 3, 2022Inventors: Yongjuan Gao, Shixiang Jia, Yuncheng Zheng, Yingying Jin, Zhu Wang, Zhao Dong, Si Chen, Bill Nai-chau Sun, Qiang Li
-
Publication number: 20210395354Abstract: The invention provides an antibody and/or an antigen binding fragment that binds to NGF, and the amino acid sequences of the heavy chain and light chain variable regions of the antibody. The NGF antibody and/or its antigen binding fragment provided by the invention has high affinity for NGF and can effectively block the binding between NGF receptor and NGF. This antibody and/or its antigen binding fragment can inhibit the binding activity of NGF and its receptor in vitro, and is suitable for the treatment of pain diseases which are related to the haughty expression or increased expression of NGF.Type: ApplicationFiled: June 23, 2020Publication date: December 23, 2021Inventors: Zhu Wang, Yongjuan Gao, Si Chen, Cecily Rou-Yun Sun, Yuncheng Zheng, Bill Nai-Chau Sun, Qiang Li
-
Patent number: 11123438Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.Type: GrantFiled: November 16, 2016Date of Patent: September 21, 2021Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.Inventors: Qiang Li, Yuanli Li, Si Chen, Zhu Wang, Zhao Dong, Zirui Li, Xinlu Ma, Lu Yang, Yongjuan Gao, Yuncheng Zheng, Naichao Sun
-
Publication number: 20200157185Abstract: A hyperglycosylated recombinant human coagulation factor IX (FIX) fusion protein, a preparation method therefor, and use thereof. The fusion protein sequentially comprises, from N- to C-terminus, a human FIX, a flexible peptide linker, at least one human chorionic gonadotropin ? subunit carboxy-terminal peptide rigid unit, and a half-life extending moiety. The fusion protein has a biological activity similar to that of the recombinant FIX, an extended in vivo activity half-life, and reduced immunogenicity, so as to improve pharmacokinetics and pharmacodynamics.Type: ApplicationFiled: April 10, 2017Publication date: May 21, 2020Inventors: YongJuan Gao, Si Chen, Zirui Li, Xiaoping Tu, Bill Nai-chau Sun, Qiang Li
-
Publication number: 20190365867Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.Type: ApplicationFiled: November 16, 2016Publication date: December 5, 2019Inventors: Qiang LI, Wenchen ZHU, Yuanli LI, Chenggong ZHU, Yongjuan GAO, Zijia REN, Luyan ZHU, Naichao SUN, Xiaoshan WANG, Bin LIU, Zhi LI, Wenwen WANG, Ming JIANG, Qilei WANG, Lirui WANG, Shuya WANG, Songlin ZHU, Jie GAO, Hongsheng SU
-
Publication number: 20190184026Abstract: A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin ?-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein.Type: ApplicationFiled: November 16, 2016Publication date: June 20, 2019Inventors: Qiang LI, Yuanli LI, Si CHEN, Zhu WANG, Zhao DONG, Zirui LI, Xinlu MA, Lu YANG, Yongjuan GAO, Yuncheng ZHENG, Naichao SUN